The combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer.
Alice Lallo, Kristopher K Frese, Christopher Morrow, Robert Szczepaniak Sloane, Sakshi Gulati, Maximilian W Schenk, Francesca Trapani, Nicole Simms, Melanie Galvin, Stewart Brown, Cassandra L Hodgkinson, Lynsey Priest, Adina M Hughes, Zhongwu Lai, Elaine B Cadogan, Garima Khandelwal, Kathryn L Simpson, Crispin Miller, Fiona H Blackhall, Mark J O'ConnorCaroline Dive
Research output: Contribution to journal › Article › peer-review
335Downloads
(Pure)
Fingerprint
Dive into the research topics of 'The combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer.'. Together they form a unique fingerprint.